Therefore, while the Western blot assessment of LC3B-II and p62 levels in the tumor and liver suggest that the liposomal HCQ formulation in combination with gefitinib was more effective at inhibiting autophagy in vivo, the efficacy data could suggest that autophagy inhibition did not engender significantly improved therapeutic effects. Here, MAP1LC3B is linked to neoplasm.